Martindale Pharma gains regulatory approval for pediatric clobazam oral suspension in seven European countries

Martindale Pharma, a UK-based pharmaceutical company focused on specialty and hospital-initiated medicines, has achieved a significant milestone with the regulatory approval of its clobazam oral suspension formulations in seven European countries. These approvals mark a strategic advance in the company’s long-standing mission to improve drug accessibility for vulnerable patient populations, particularly children and the elderly, who may face challenges with solid oral dosage forms. Branded as Epaclob and Silocalm, the formulations represent the first licensed liquid versions of clobazam to be introduced across multiple European markets, expanding the availability of safe and consistent dosing alternatives for patients requiring antiepileptic therapies.

What is Epaclob and How Does it Support Epilepsy Treatment?

Epaclob is a clobazam oral suspension developed as a user-friendly alternative to conventional clobazam tablets. Clobazam, a benzodiazepine derivative, is widely prescribed as an adjunctive treatment for various forms of epilepsy, including Lennox-Gastaut syndrome and refractory epilepsy. While its therapeutic value is well documented, the availability of the drug in liquid form has historically been limited. This limitation has posed a challenge for pediatric patients, individuals with dysphagia, and others who are unable to swallow tablets.

Martindale Pharma’s introduction of Epaclob and its counterpart Silocalm addresses this gap by offering a ready-to-use, stable liquid formulation that ensures dosing flexibility and accuracy. These features are especially critical in pediatric neurology, where small variances in medication quantity can significantly affect outcomes. The oral suspension format reduces the need for compounding or tablet manipulation in clinical or home settings, mitigating the risk of dosing inconsistencies that may result from informal modifications of solid dosage forms.

Which European Countries Have Approved Epaclob and Silocalm?

The regulatory approvals span seven European countries, highlighting Martindale Pharma’s success in navigating a diverse regulatory landscape. Epaclob has received marketing authorisation in France, Ireland, Germany, and Italy. Simultaneously, the formulation has been approved under the brand name Silocalm in Denmark, Spain, and Iceland. This dual-brand approach reflects Martindale Pharma’s market-specific strategy, allowing the company to tailor branding and regulatory submissions in alignment with national guidelines and language requirements.

The simultaneous expansion into these key European markets underscores the strength of Martindale Pharma’s regulatory affairs team and their capability to meet varying compliance frameworks across the continent. By achieving approval in this broad set of countries, the company not only extends its commercial footprint but also enhances access to an essential formulation for pediatric epilepsy patients who previously had limited options outside of the United Kingdom.

What Did Martindale Pharma’s CEO Say About the Approval?

Michael Harris, Chief Executive Officer of Martindale Pharma at the time of the announcement, commented that the approvals represented an important validation of the company’s product development focus and international expansion goals. He emphasised that the liquid formulation had already been successfully established in the UK and had proven itself as a valuable treatment option for both patients and prescribers. Harris noted that the oral liquid form of clobazam offered significant advantages in terms of ease of use and dosing precision, particularly for young patients. He reaffirmed the company’s commitment to delivering safe, high-quality, and innovative pharmaceutical solutions across international markets.

The comments from the company’s leadership reinforce the strategic direction Martindale Pharma has taken in recent years, pivoting toward unmet needs within hospital-initiated and paediatric medicine niches. By advancing novel formulations of well-established molecules like clobazam, the company positions itself as both a solutions-oriented provider and a trusted partner in the broader European pharmaceutical landscape.

What Makes This Formulation First-of-Its-Kind?

Clobazam has long been part of the antiepileptic arsenal used by neurologists and paediatricians. However, until the launch of Martindale Pharma’s Tapclob in the UK in May 2013, no licensed oral liquid suspension of the drug had been made widely available. While unlicensed compounding options existed, they varied significantly in consistency, stability, and safety. Martindale’s version brought a formulation with standardised concentration, shelf-life data, and regulatory oversight, making it the first of its kind in this specific format.

The significance of such a development is particularly relevant in paediatrics, where dose adjustments based on body weight are common and where adherence often depends on palatable and easy-to-administer dosage forms. The formulation’s availability in 5mg/5ml and 10mg/5ml strengths allows clinicians to select the most appropriate concentration, enhancing the flexibility of treatment regimens without compromising on precision.

How Is the Product Packaged and What Benefits Does It Offer?

Both Epaclob and Silocalm are packaged with dosing syringes and dosage caps, which are included to support accurate and reproducible dose administration. These components are vital to ensuring that patients, caregivers, and healthcare professionals can maintain dosing integrity, particularly in home environments or non-specialist care settings where measurement errors can occur. The inclusion of these tools within the standard product packaging exemplifies Martindale Pharma’s attention to practical aspects of treatment delivery, aligning with modern patient-centric drug design principles.

The design and distribution of the product also offer logistical benefits. By providing a commercially prepared, ready-to-use formulation, Martindale Pharma reduces the dependency on individual pharmacies to compound the drug—a process that can vary in quality and stability. In doing so, the company contributes to more predictable therapeutic outcomes and enhanced pharmacovigilance tracking.

What Is the Regulatory and Market Context in Europe?

As of 2016, European regulatory bodies have increasingly emphasised the need for age-appropriate formulations in paediatric care. Agencies such as the European Medicines Agency (EMA) have been encouraging pharmaceutical companies to develop child-friendly versions of existing medications as part of wider paediatric initiatives and licensing frameworks. This regulatory environment has incentivised innovation in formulation science, with companies focusing not only on new molecules but also on improving delivery mechanisms of established drugs.

Within this context, Martindale Pharma’s successful push to license a paediatric clobazam oral suspension in seven countries fits neatly into broader policy and healthcare objectives across the European Union. By contributing to the availability of standardised, approved alternatives to extemporaneous preparations, the company also helps reduce risks related to inconsistent compounding practices, which remain a challenge in many health systems.

What Does This Mean for Martindale Pharma’s Strategic Expansion?

The multi-country approval for Epaclob and Silocalm signals an inflection point in Martindale Pharma’s European strategy. Historically known for its presence in the UK, the company has been seeking to scale its business internationally by focusing on high-need therapeutic categories and specialised dosage forms. This approval opens new revenue channels while aligning Martindale’s portfolio with contemporary regulatory and clinical trends.

From a commercial perspective, the company enters markets with large epilepsy patient populations and well-established reimbursement systems for paediatric neurology care. Its liquid formulation provides a differentiated product offering that is likely to gain attention from neurologists, pharmacists, and healthcare purchasers alike.

What Are the Clinical and Commercial Takeaways?

As of October 2016, Martindale Pharma’s Epaclob and Silocalm formulations represent a clinically significant advancement in epilepsy treatment across Europe. They offer a reliable, licensed alternative to previously unregulated liquid preparations, contributing to safer prescribing practices and better patient adherence. The approvals reinforce the pharmaceutical industry’s shift toward dosage forms that cater to individual patient needs, rather than adopting a one-size-fits-all approach to drug development.

The company’s achievement not only reflects its regulatory expertise and product innovation capabilities but also illustrates how a focused pharmaceutical firm can carve out a leadership position in targeted therapeutic niches. In expanding the reach of its clobazam oral suspension, Martindale Pharma brings a timely and relevant solution to European epilepsy care, supporting both improved treatment outcomes and healthcare system efficiencies.